Syros Pharmaceuticals Q1 2024 GAAP EPS $(0.10) Beats $(0.86) Estimate, Cash (Incl Restricted Cash) $85.64M
Portfolio Pulse from Benzinga Newsdesk
Syros Pharmaceuticals (SYRS) reported a Q1 2024 GAAP EPS of $(0.10), surpassing the $(0.86) estimate, marking an 88.37% beat and an 88.24% improvement from the previous year's $(0.85) loss per share. The company also reported having $85.64M in cash, including restricted cash.
May 14, 2024 | 10:47 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Syros Pharmaceuticals reported a significant beat on Q1 2024 earnings estimates with a smaller loss than expected and showed a strong year-over-year improvement. The company's cash position remains robust.
The significant beat on earnings estimates and the improvement in losses compared to the previous year are likely to be viewed positively by investors. The strong cash position indicates financial stability, which could further bolster investor confidence in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100